Page last updated: 2024-09-04

mdl 100240 and angiotensin ii

mdl 100240 has been researched along with angiotensin ii in 5 studies

Compound Research Comparison

Studies (mdl 100240)	Trials (mdl 100240)	Recent Studies (post-2010) (mdl 100240)	Studies (angiotensin ii)	Trials (angiotensin ii)	Recent Studies (post-2010) (angiotensin ii)
21	9	0	38,152	1,089	7,413

Protein Interaction Comparison

Protein	Taxonomy	angiotensin ii (IC50)
Atrial natriuretic peptide receptor 3	Homo sapiens (human)	0.002
Type-1A angiotensin II receptor	Rattus norvegicus (Norway rat)	0.002
Type-1B angiotensin II receptor	Rattus norvegicus (Norway rat)	0.0018
Type-1 angiotensin II receptor	Homo sapiens (human)	0.0055
Type-2 angiotensin II receptor	Rattus norvegicus (Norway rat)	0.004
Type-2 angiotensin II receptor	Homo sapiens (human)	0.0011

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (60.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bennett, T; Brunner-Ferber, F; Gardiner, SM; Kemp, PA	1
Biollaz, J; Brunner, HR; Brunner-Ferber, F; Buclin, T; Nussberger, J; Rousso, P	1
Biollaz, J; Brunner, HR; Brunner-Ferber, F; Buclin, T; Décosterd, LA; La Roche, SD; Nussberger, J; Rousso, P	1
Agabiti-Rosei, E; Bova, S; Neri, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP; Sacchetto, A	1
Agabiti-Rosei, E; Bova, S; Cavallin, M; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Rizzoni, D; Rossi, GP	1

Trials

2 trial(s) available for mdl 100240 and angiotensin ii

Article	Year
Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. Journal of cardiovascular pharmacology, 1998, Volume: 31, Issue:3 Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Benzazepines; Blood Pressure; Double-Blind Method; Enzyme Inhibitors; Humans; Male; Neprilysin; Placebos; Pyridines; Reference Values	1998
Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers. Journal of hypertension, 1999, Volume: 17, Issue:3 Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Endocrine System; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Posture; Pyridines; Reference Values; Renal Plasma Flow, Effective; Safety; Stereoisomerism	1999

Article

Year

Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers.

Journal of cardiovascular pharmacology, 1998, Volume: 31, Issue:3

Topics: Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Area Under Curve; Benzazepines; Blood Pressure; Double-Blind Method; Enzyme Inhibitors; Humans; Male; Neprilysin; Placebos; Pyridines; Reference Values

1998

Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers.

Journal of hypertension, 1999, Volume: 17, Issue:3

Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Endocrine System; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney; Male; Neprilysin; Peptidyl-Dipeptidase A; Posture; Pyridines; Reference Values; Renal Plasma Flow, Effective; Safety; Stereoisomerism

1999

Other Studies

3 other study(ies) available for mdl 100240 and angiotensin ii

Article	Year
Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats. British journal of pharmacology, 1997, Volume: 122, Issue:8 Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzazepines; Bradykinin; Endothelin-1; Hemodynamics; Male; Neprilysin; Protease Inhibitors; Pyridines; Rats	1997
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension. American journal of hypertension, 2002, Volume: 15, Issue:2 Pt 1 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Aorta; Benzazepines; Blood Pressure; Body Weight; Cardiovascular Diseases; Hypertension; In Vitro Techniques; Male; Neprilysin; Organ Size; Pyridines; Ramipril; Rats; Vasoconstriction	2002
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor. Journal of hypertension, 2002, Volume: 20, Issue:7 Topics: Adrenomedullin; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Pressure; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Heart; Hypertension; Male; Models, Cardiovascular; Neprilysin; Organ Size; Peptides; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Receptor, Bradykinin B2; Receptors, Bradykinin; Severity of Illness Index; Systole; Treatment Outcome; Vasoconstrictor Agents	2002